News

News Subscription

Dec 06. 2019
Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million
Read more
Download
Oct 30. 2019
Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference
Read more
Download
Oct 29. 2019
Basilea reports marketing authorization of antifungal Cresemba® in Brazil
Read more
Download
Sep 30. 2019
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
Read more
Download
Aug 27. 2019
Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer
Read more
Download
Aug 20. 2019
Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
Read more
Download
Aug 13. 2019
Basilea starts phase 1/2 study with derazantinib in urothelial cancer
Read more
Download
Aug 06. 2019
Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)
Read more
Download
Jul 01. 2019
Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
Read more
Download
Jun 03. 2019
Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting
Read more
Download